SG11201809381XA - Polynucleotides encoding interleukin-12 (il12) and uses thereof - Google Patents

Polynucleotides encoding interleukin-12 (il12) and uses thereof

Info

Publication number
SG11201809381XA
SG11201809381XA SG11201809381XA SG11201809381XA SG11201809381XA SG 11201809381X A SG11201809381X A SG 11201809381XA SG 11201809381X A SG11201809381X A SG 11201809381XA SG 11201809381X A SG11201809381X A SG 11201809381XA SG 11201809381X A SG11201809381X A SG 11201809381XA
Authority
SG
Singapore
Prior art keywords
cambridge
modernatx
massachusetts
square
international
Prior art date
Application number
SG11201809381XA
Inventor
Joshua Frederick
Susannah Hewitt
Ailin Bai
Stephen Hoge
Vladimir Presnyak
Iain Mcfadyen
Kerry Benenato
Ellalahewage Sathyajith Kumarasinghe
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58794205&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201809381X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of SG11201809381XA publication Critical patent/SG11201809381XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 November 2017 (23.11.2017) WIPO I PCT omit VIII two III VIII NEE 111°011mm oimIE (10) International Publication Number WO 2017/201350 Al (51) International Patent Classification: A61K 38/20 (2006.01) Cl 2N 15/67 (2006.01) CO7K 14/54 (2006.01) (21) International Application Number: PCT/US2017/033422 (22) International Filing Date: 18 May 2017 (18.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/338,483 18 May 2016 (18.05.2016) US 62/443,693 07 January 2017 (07.01.2017) US SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) 1-1 kr) O 1-1 O N _ N O 1-1 N C (71) Applicant: MODERNATX, INC. [US/US]; 200 Technol- with sequence listing part of description (Rule 5.2(a)) ogy Square, Cambridge, Massachusetts 02139 (US). (72) Inventors: FREDERICK, Joshua; c/o MODERNATX, INC., 200 Technology Square, Cambridge, Massachu- setts 02139 (US). HEWITT, Susannah; c/o MODER- NATX, INC., 200 Technology Square, Cambridge, Mass- achusetts 02139 (US). BAI, Ailin; c/o MODERNATX, INC., 200 Technology Square, Cambridge, Massachu- setts 02139 (US). HOGE, Stephen; c/o MODERNATX, INC., 200 Technology Square, Cambridge, Massachusetts 02139 (US). PRESNYAK, Vladimir; c/o MODERNATX, INC., 200 Technology Square, Cambridge, Massachusetts 02139 (US). MCFADYEN, Iain; c/o MODERNATX, INC., 200 Technology Square, Cambridge, Massachusetts 02139 (US). BENENATO, Kerry; c/o MODERNATX, INC., 200 Technology Square, Cambridge, Massachusetts 02139 (US). KUMARASINGHE, Ellalahewage Sathya- jith; c/o MODERNATX, INC., 200 Technology Square, Cambridge, Massachusetts 02139 (US). (74) Agent: MANDRAGOURAS, Amy, E. et al.; Nelson Mullins Riley & Scarborough LLP, One Post Office Square, Boston, Massachusetts 02109-2127 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (54) Title: POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF (57) : The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open read- ing frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence opti- mized polynucleotides.
SG11201809381XA 2016-05-18 2017-05-18 Polynucleotides encoding interleukin-12 (il12) and uses thereof SG11201809381XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338483P 2016-05-18 2016-05-18
US201762443693P 2017-01-07 2017-01-07
PCT/US2017/033422 WO2017201350A1 (en) 2016-05-18 2017-05-18 Polynucleotides encoding interleukin-12 (il12) and uses thereof

Publications (1)

Publication Number Publication Date
SG11201809381XA true SG11201809381XA (en) 2018-12-28

Family

ID=58794205

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809381XA SG11201809381XA (en) 2016-05-18 2017-05-18 Polynucleotides encoding interleukin-12 (il12) and uses thereof

Country Status (22)

Country Link
US (5) US10646549B2 (en)
EP (2) EP3458083B1 (en)
JP (2) JP7246930B2 (en)
KR (2) KR102469450B1 (en)
CN (1) CN109195621A (en)
AU (1) AU2017268397B2 (en)
CA (1) CA3024470A1 (en)
DK (1) DK3458083T3 (en)
ES (1) ES2941411T3 (en)
FI (1) FI3458083T3 (en)
HR (1) HRP20230050T1 (en)
HU (1) HUE061077T2 (en)
IL (1) IL262501A (en)
LT (1) LT3458083T (en)
MX (2) MX2018013509A (en)
PL (1) PL3458083T3 (en)
PT (1) PT3458083T (en)
RS (1) RS63912B1 (en)
RU (1) RU2769316C2 (en)
SG (1) SG11201809381XA (en)
SI (1) SI3458083T1 (en)
WO (1) WO2017201350A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
JP2016538829A (en) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Polynucleotide encoding low density lipoprotein receptor
CN105939767B (en) 2014-01-08 2018-04-06 弗洛设计声能学公司 Sound electrophoretic apparatus with alliteration electrophoresis chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
AU2016324310B2 (en) 2015-09-17 2021-04-08 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
PL3718565T3 (en) 2015-10-22 2022-09-19 Modernatx, Inc. Respiratory virus vaccines
PL3394030T3 (en) 2015-12-22 2022-04-11 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
KR102469450B1 (en) 2016-05-18 2022-11-22 모더나티엑스, 인크. Polynucleotides Encoding Interleukin-12 (IL12) and Uses Thereof
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
MA50335A (en) * 2016-12-08 2020-08-19 Modernatx Inc NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
CA3055653A1 (en) * 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
HUE060693T2 (en) * 2017-03-15 2023-04-28 Modernatx Inc Compound and compositions for intracellular delivery of therapeutic agents
EP3596042B1 (en) 2017-03-15 2022-01-12 Modernatx, Inc. Crystal forms of amino lipids
MA48047A (en) 2017-04-05 2020-02-12 Modernatx Inc REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
WO2018213731A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
MA49922A (en) 2017-08-18 2021-06-02 Modernatx Inc PROCESSES FOR HPLC ANALYSIS
JP7408098B2 (en) 2017-08-18 2024-01-05 モデルナティエックス インコーポレイテッド RNA polymerase variants
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
AU2018385759B2 (en) 2017-12-14 2021-10-21 Flodesign Sonics, Inc. Acoustic transducer driver and controller
CA3101969A1 (en) * 2018-05-31 2019-12-05 Beth Israel Deaconess Medical Center Rna-aided immunotherapeutics
CN112399860A (en) 2018-06-06 2021-02-23 麻省理工学院 Circular RNA for translation in eukaryotic cells
GB2600800B (en) 2018-09-04 2023-08-16 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
CN112996519A (en) 2018-09-04 2021-06-18 德克萨斯大学***董事会 Compositions and methods for organ-specific delivery of nucleic acids
US20230081530A1 (en) * 2018-09-14 2023-03-16 Modernatx, Inc. Methods and compositions for treating cancer using mrna therapeutics
KR102524247B1 (en) * 2018-12-21 2023-04-21 가톨릭대학교 산학협력단 p40-EBI3 COMPLEX AND USES THEREOF
WO2020146700A1 (en) * 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Lipid nanoparticles
TW202043256A (en) 2019-01-10 2020-12-01 美商健生生物科技公司 Prostate neoantigens and their uses
KR20210152480A (en) * 2019-03-14 2021-12-15 엔진 인코포레이티드 Chitosan polyplex-based local expression of IL-12 alone or in combination with type-I IFN inducers for the treatment of mucosal cancer
CN109932511B (en) * 2019-03-22 2020-02-04 南昌大学第二附属医院 Urine exosome phospholipid marker for liver cancer screening and kit thereof
WO2020209934A1 (en) * 2019-04-11 2020-10-15 Massachusetts Institute Of Technology Novel chimeric antigen receptors and libraries
CA3139032A1 (en) 2019-05-22 2020-11-26 Robert Alexander WESSELHOEFT Circular rna compositions and methods
JP2022548304A (en) 2019-09-19 2022-11-17 モデルナティエックス インコーポレイテッド Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
EP3920976B1 (en) 2019-12-04 2023-07-19 Orna Therapeutics, Inc. Circular rna compositions and methods
EP4106730A4 (en) * 2020-02-19 2024-03-27 Univ Florida Multilamellar rna nanoparticles and methods of sensitizing tumors to treatment with immune checkpoint inhibitors
KR20220144831A (en) 2020-02-21 2022-10-27 콤바인드 테라퓨틱스, 인코포레이션 Compositions and methods for organ protective expression and modulation of encoding ribonucleic acids
WO2021204179A1 (en) 2020-04-09 2021-10-14 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
BR112022020203A2 (en) 2020-04-09 2022-11-22 Suzhou Abogen Biosciences Co Ltd COMPOSITION OF LIPID NANOPARTICLES
WO2021233849A1 (en) 2020-05-17 2021-11-25 Boehringer Ingelheim International Gmbh Viral vectors and nucleic acids for regulated gene therapy
CN116710079A (en) 2020-07-24 2023-09-05 斯特兰德生物科技公司 Lipid nanoparticles comprising modified nucleotides
JP2024503000A (en) 2021-01-08 2024-01-24 ストランド セラピューティクス インコーポレイテッド Expression constructs and their use
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
CN113509542A (en) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 Medicine for expressing interleukin 12 and aiming at tumor based on mRNA and preparation method thereof
US20230263742A1 (en) * 2021-05-06 2023-08-24 Stemirna Therapeutics Co., Ltd. A lipid
IL309505A (en) 2021-09-03 2024-02-01 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
CN116829578A (en) * 2021-10-08 2023-09-29 苏州艾博生物科技有限公司 Polynucleotides encoding interleukin-12 (IL-12) and compositions and methods related thereto
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
CN116179549A (en) 2021-12-08 2023-05-30 南京吉迈生物技术有限公司 Modification of gene transcription and translation efficiency by 5' UTR sequence variants
CN114044741B (en) * 2022-01-13 2022-04-15 北京悦康科创医药科技股份有限公司 Cationic lipid compound, composition containing same and application
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
WO2023196988A1 (en) * 2022-04-07 2023-10-12 Modernatx, Inc. Methods of use of mrnas encoding il-12
CN116621965A (en) * 2022-05-06 2023-08-22 珠海丽凡达生物技术有限公司 Therapeutic nucleic acid molecules, mixtures, medicaments and their use in the treatment of solid tumors
CN114994331B (en) * 2022-05-17 2023-02-24 无锡科金生物科技有限公司 Kit for detecting protein expression level and preparation method and application thereof
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US6140496A (en) 1990-10-09 2000-10-31 Benner; Steven Albert Precursors for deoxyribonucleotides containing non-standard nucleosides
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5922685A (en) 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
CA2268276A1 (en) 1996-10-18 1998-04-30 Jeff Nordstrom Gene expression and delivery systems and uses
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
JP2001521759A (en) 1997-11-12 2001-11-13 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド Translational enhancer element of human amyloid precursor protein gene
EP1987845B1 (en) 1997-11-20 2012-03-21 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor.
US7521178B1 (en) 1998-04-23 2009-04-21 Takara Bio Inc. Method for synthesizing DNA
EP1030680A4 (en) 1998-09-15 2003-05-02 Genetics Inst Treatment of kaposi's sarcoma with il-12
AU6270499A (en) 1998-09-29 2000-04-17 Phylos, Inc. Synthesis of codon randomized nucleic acids
EP2829609A1 (en) 1999-08-24 2015-01-28 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
DE60113805T2 (en) 2000-01-20 2006-07-13 Universität Zürich Institut für Medizinische Virologie Intratumoral administration of naked IL-12-encoding nucleic acid molecules
US7468275B2 (en) 2000-01-28 2008-12-23 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying same
WO2001055369A1 (en) 2000-01-28 2001-08-02 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying same
ES2164011B1 (en) 2000-02-25 2003-05-16 Inst Cientifico Tecnol Navarra COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS.
ES2272448T3 (en) 2000-03-15 2007-05-01 Genexine Co., Ltd. GENES OF THE IL-12P40 MUNATE SUBUNITY TO IMPROVE THE ACTIVITY OF IL-12 AND USE OF THEMSELVES IN A GENETIC VACCINE COADYUVANT.
KR20020010206A (en) 2000-07-27 2002-02-04 이시우 DNA vector comprising a single chain IL-12 and B7.1, and Anti-cancer cell vaccine transformed with the above vector
ES2340532T3 (en) 2001-06-05 2010-06-04 Curevac Gmbh MRNA WITH AN INCREASED G / C CONTENT THAT CODIFIES FOR A BACTERIAL ANTIGEN AND USING THE SAME.
WO2003004685A2 (en) 2001-07-03 2003-01-16 University Of Utah Research Foundation Soluble steroidal peptides for nucleic acid delivery
EP2428571B1 (en) 2001-09-28 2018-07-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
EP1452593B1 (en) 2001-11-14 2009-04-08 Toyo Boseki Kabushiki Kaisha Dna synthesis promoters, dna polymerase-associated factors and utilization thereof
CA2409775C (en) 2001-12-03 2010-07-13 F. Hoffmann-La Roche Ag Reversibly modified thermostable enzymes for dna synthesis and amplification in vitro
AU2003228440B2 (en) 2002-04-01 2008-10-02 Walter Reed Army Institute Of Research Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
DE10248141B4 (en) 2002-10-11 2007-04-19 Universitätsklinikum Hamburg-Eppendorf Nucleic acids and their use for gene therapy
DE10260805A1 (en) 2002-12-23 2004-07-22 Geneart Gmbh Method and device for optimizing a nucleotide sequence for expression of a protein
WO2004110371A2 (en) 2003-05-30 2004-12-23 University Of South Florida Method for the treatment of malignancies
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
GB0329146D0 (en) 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
DE102004042546A1 (en) 2004-09-02 2006-03-09 Curevac Gmbh Combination therapy for immune stimulation
EP1640018A1 (en) 2004-09-24 2006-03-29 Universität Zürich Combinational therapy for treating cancer
LT2439273T (en) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US7550264B2 (en) 2005-06-10 2009-06-23 Datascope Investment Corporation Methods and kits for sense RNA synthesis
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
CA2613442C (en) 2005-06-30 2016-08-23 Archemix Corp. Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
CN105330741B (en) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
ES2937245T3 (en) 2005-08-23 2023-03-27 Univ Pennsylvania RNA containing modified nucleosides and methods of using the same
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
WO2007025008A2 (en) 2005-08-24 2007-03-01 The Scripps Research Institute Translation enhancer-element dependent vector systems
DE102005046490A1 (en) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency
PT1966238E (en) 2005-12-30 2012-07-31 Merck Patent Gmbh Interleukin-12p40 variants with improved stability
EP2591794A1 (en) 2006-01-05 2013-05-15 The Ohio State University Research Foundation MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors
CA2633754C (en) 2006-01-05 2013-06-18 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007084364A2 (en) 2006-01-13 2007-07-26 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Improved il-12 for expression in mammalian cells
KR101241477B1 (en) 2006-01-27 2013-03-08 엘지이노텍 주식회사 Nitride semiconductor light-emitting device and manufacturing method thereof
EP2522749A1 (en) 2006-03-02 2012-11-14 The Ohio State University MicroRNA expression profile associated with pancreatic cancer
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US20080046192A1 (en) 2006-08-16 2008-02-21 Richard Lathrop Polypepetide-encoding nucleotide sequences with refined translational kinetics and methods of making same
EP2115138A2 (en) 2006-09-19 2009-11-11 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
DE102006051516A1 (en) 2006-10-31 2008-05-08 Curevac Gmbh (Base) modified RNA to increase the expression of a protein
WO2008054828A2 (en) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
CN101622348A (en) 2006-12-08 2010-01-06 奥斯瑞根公司 Gene and the approach regulated as the miR-20 of targets for therapeutic intervention
CA2673029C (en) 2006-12-22 2017-03-28 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
ES2654303T3 (en) 2007-05-04 2018-02-13 University Health Network IL-12 immunotherapy against cancer
WO2008147974A1 (en) 2007-05-23 2008-12-04 University Of South Florida Micro-rnas modulating immunity and inflammation
WO2008154098A2 (en) 2007-06-07 2008-12-18 Wisconsin Alumni Research Foundation Reagents and methods for mirna expression analysis and identification of cancer biomarkers
DK2170959T3 (en) 2007-06-18 2014-01-13 Merck Sharp & Dohme ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
TWI359030B (en) 2007-08-24 2012-03-01 Univ Nat Taiwan Treatment of cellular proliferative disorders
PT2201100E (en) 2007-09-14 2016-06-03 Univ Brussel Vrije Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
US20110086904A1 (en) 2007-09-17 2011-04-14 The Trustees Of The University Of Pennsylvania GENERATION OF HYPERSTABLE mRNAs
EP2591804A3 (en) * 2007-09-24 2014-04-16 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
KR101541935B1 (en) 2007-09-26 2015-08-05 인트렉손 코포레이션 Synthetic 5'UTRs, expression vectors, and methods for increasing transgene expression
JP2011505143A (en) 2007-11-30 2011-02-24 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション MicroRNA expression profiling and peripheral blood targeting in lung cancer
EP2610340B1 (en) 2007-12-11 2014-10-01 The Scripps Research Institute Compositions and methods related to mRNA translational enhancer elements
EP2072618A1 (en) 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
JP5749494B2 (en) * 2008-01-02 2015-07-15 テクミラ ファーマシューティカルズ コーポレイション Improved compositions and methods for delivery of nucleic acids
WO2009100430A2 (en) 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
US20110052502A1 (en) 2008-02-28 2011-03-03 The Ohio State University Research Foundation MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CCL) and Uses Thereof
AU2009238175C1 (en) * 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
EP2112235A1 (en) 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma
WO2009140206A1 (en) 2008-05-11 2009-11-19 The Gov. Of The U. S. A., As Represented By The Secretary Of The Dept. Of Health And Human Services Improved expression of il-12 family heterodimers
PL215513B1 (en) 2008-06-06 2013-12-31 Univ Warszawski New borane phosphate analogs of dinucleotides, their application, RNA particle, method of obtaining RNA and method of obtaining peptides or protein
US8401798B2 (en) 2008-06-06 2013-03-19 Dna Twopointo, Inc. Systems and methods for constructing frequency lookup tables for expression systems
US7561973B1 (en) 2008-07-31 2009-07-14 Dna Twopointo, Inc. Methods for determining properties that affect an expression property value of polynucleotides in an expression system
US8126653B2 (en) 2008-07-31 2012-02-28 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
WO2009149539A1 (en) 2008-06-10 2009-12-17 Université de Montréal Enhancing antigen-specific cd8+ t cell response using irf-7 mrna
WO2010018563A2 (en) 2008-08-12 2010-02-18 Rosetta Genomics Ltd. Compositions and methods for the prognosis of lymphoma
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
US9074206B2 (en) 2008-11-13 2015-07-07 Fudan University Compositions and methods for micro-RNA expression profiling of colorectal cancer
SI2376535T1 (en) 2008-12-09 2017-07-31 F. Hoffmann-La Roche Ag Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2358902A1 (en) 2008-12-10 2011-08-24 Universität Regensburg Compositions and methods for micro-rna expression profiling of cancer stem cells
CA2760446C (en) 2009-04-30 2018-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
WO2010129860A2 (en) 2009-05-08 2010-11-11 The Ohio State University Research Foundation Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof
DK2440183T3 (en) 2009-06-10 2018-10-01 Arbutus Biopharma Corp Improved lipid formulation
EP2459231B1 (en) 2009-07-31 2016-06-08 Ethris Gmbh Rna with a combination of unmodified and modified nucleotides for protein expression
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
US20110082055A1 (en) 2009-09-18 2011-04-07 Codexis, Inc. Reduced codon mutagenesis
JP2013512251A (en) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Simultaneous inhibition of PD-L1 / PD-L2
PL3338765T3 (en) 2009-12-01 2019-06-28 Translate Bio, Inc. Steroid derivative for the delivery of mrna in human genetic diseases
WO2011076142A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expession profiling in plasma of colorectal cancer
WO2011076143A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expression profiling of lung cancer
EP2341145A1 (en) 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
WO2011094683A2 (en) 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of identifying myelodysplastic syndromes
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer
WO2011113030A2 (en) 2010-03-11 2011-09-15 H.Lee Moffitt Cancer Center & Research Institute Human cancer micro-rna expression profiles predictive of chemo-response
WO2011157294A1 (en) 2010-06-16 2011-12-22 Universita' Degli Studi Di Padova Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
US20130230884A1 (en) 2010-07-16 2013-09-05 John Chaput Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation
WO2012038448A1 (en) 2010-09-21 2012-03-29 Riboxx Gmbh Method for synthesizing rna using dna template
WO2012072096A1 (en) 2010-12-03 2012-06-07 Biontech Ag Method for cellular rna expression
KR20120066952A (en) 2010-12-15 2012-06-25 주식회사 롤팩 Antibacterial vacuum film having 7 layers structure and method for manufacturing the same
EP2651445A2 (en) 2010-12-16 2013-10-23 SPRNA GmbH Pharmaceutical composition consisting of rna having alkali metal as counter ion and formulated with dications
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
CN103476943A (en) 2011-03-10 2013-12-25 普罗维克图斯药品公司 Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2012151212A1 (en) 2011-05-01 2012-11-08 University Of Rochester Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
EP2706690B1 (en) 2011-05-02 2018-03-21 LG Electronics Inc. Method for transmitting/receiving data in wireless access system and base station for same
WO2012153187A2 (en) 2011-05-06 2012-11-15 Xentech Markers for cancer prognosis and therapy and methods of use
EP4043025A1 (en) 2011-06-08 2022-08-17 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
ES2610245T3 (en) 2011-07-15 2017-04-26 Leo Pharma A/S MicroRNA profiling for diagnosis in cutaneous T-cell lymphoma (CTCL)
US20150080243A1 (en) 2011-09-01 2015-03-19 Allegro Diagnostics Corp. Methods and compositions for detecting cancer based on mirna expression profiles
WO2013039857A1 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
CA2850624A1 (en) 2011-10-03 2013-04-11 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2013053775A1 (en) 2011-10-11 2013-04-18 Universität Zürich Prorektorat Mnw Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
WO2013066678A1 (en) 2011-10-26 2013-05-10 Georgetown University Microrna expression profiling of thyroid cancer
KR101981873B1 (en) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 Anti-pd-l1 antibodies and uses thereof
KR20220132652A (en) 2011-12-12 2022-09-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
CA2868398A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
EP2672197A1 (en) 2012-06-06 2013-12-11 Hörmann Energietechnik GmbH & Co. KG Mounting assembly for mounting plate-like bodies to the roof of a building
EP3884949A1 (en) 2012-06-08 2021-09-29 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies Nuclease resistant polynucleotides and uses thereof
US20140020675A1 (en) 2012-07-18 2014-01-23 Chandrashekhar Sonwane Solar receiver
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
CN103555734B (en) * 2012-09-17 2015-07-15 青岛康立泰药业有限公司 Coding gene of human interleukin-12, eukaryotic host cell and expression method thereof
US20150307542A1 (en) 2012-10-03 2015-10-29 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
JP6144355B2 (en) * 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chemically modified mRNA
WO2014089486A1 (en) 2012-12-07 2014-06-12 Shire Human Genetic Therapies, Inc. Lipidic nanoparticles for mrna delivering
CA2897941A1 (en) 2013-01-17 2014-07-24 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
CN109045289A (en) 2013-02-22 2018-12-21 库瑞瓦格股份公司 Vaccine inoculation and the combination for inhibiting PD-1 approach
JP6352950B2 (en) 2013-03-08 2018-07-04 ノバルティス アーゲー Lipids and lipid compositions for active drug delivery
EP2964234A4 (en) 2013-03-09 2016-12-07 Moderna Therapeutics Inc Heterologous untranslated regions for mrna
PT2968586T (en) 2013-03-14 2018-11-13 Ethris Gmbh Cftr mrna compositions and related methods and uses
HUE055044T2 (en) 2013-03-14 2021-10-28 Translate Bio Inc Methods and compositions for delivering mrna coded antibodies
WO2014152940A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
ES2708562T3 (en) 2013-03-14 2019-04-10 Translate Bio Inc Quantitative evaluation of the efficiency of messenger RNA cover
EP2970955B1 (en) 2013-03-14 2018-11-14 Translate Bio, Inc. Methods for purification of messenger rna
KR20150127582A (en) 2013-03-14 2015-11-17 샤이어 휴먼 지네틱 테라피즈 인크. RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS
ES2680595T3 (en) 2013-03-14 2018-09-10 Translate Bio, Inc. Quantitative evaluation for efficacy of messenger RNA to cover
EP3388834B1 (en) 2013-03-15 2020-04-15 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
WO2015024667A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Method for increasing expression of rna-encoded proteins
JP6623353B2 (en) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー Anti-PD-1 antibodies and their use for therapy and diagnosis
WO2015050158A1 (en) 2013-10-01 2015-04-09 国立大学法人三重大学 T cell-inducing vaccine containing interepitope sequence promoting antigen presentation
EP3058082A4 (en) 2013-10-18 2017-04-26 ModernaTX, Inc. Compositions and methods for tolerizing cellular systems
US9629804B2 (en) 2013-10-22 2017-04-25 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger RNA
WO2015061491A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
ES2806575T3 (en) 2013-11-01 2021-02-18 Curevac Ag Modified RNA with decreased immunostimulatory properties
CA2934028A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3083666A4 (en) * 2013-12-18 2017-09-20 Intrexon Corporation Single chain il-12 nucleic acids, polypeptids, and uses thereof
SG11201603144QA (en) 2013-12-30 2016-07-28 Curevac Ag Artificial nucleic acid molecules
WO2015101415A1 (en) 2013-12-30 2015-07-09 Curevac Gmbh Artificial nucleic acid molecules
CA2946751A1 (en) 2014-04-23 2015-10-29 Modernatx, Inc. Nucleic acid vaccines
SI3766916T1 (en) * 2014-06-25 2023-01-31 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016048903A1 (en) 2014-09-22 2016-03-31 Intrexon Corporation Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College Peritumoral and intratumoral materials for cancer therapy
JP6912384B2 (en) 2015-04-22 2021-08-04 キュアバック アーゲー RNA-containing compositions for the treatment of cancer diseases
CN107847577B (en) 2015-05-19 2021-11-23 摩尔福基因有限公司 Cancer vaccine comprising mRNA encoding M-like protein
US10682401B2 (en) 2015-05-19 2020-06-16 Morphogenesis, Inc. Multi-indication mRNA cancer immunotherapy
AU2016324310B2 (en) * 2015-09-17 2021-04-08 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP3205356A1 (en) 2016-02-10 2017-08-16 Onkoloski Institut Ljubljana Plasmid expression vector encoding human interleukin 12 under transcriptional control of p21 promoter and without antibiotic resistance for cancer gene therapy and other uses thereof
ES2718192T3 (en) 2016-02-25 2019-06-28 Provecs Medical Gmbh Novel immunostimulatory vector system
KR102469450B1 (en) 2016-05-18 2022-11-22 모더나티엑스, 인크. Polynucleotides Encoding Interleukin-12 (IL12) and Uses Thereof
SG10201913631TA (en) 2016-08-19 2020-03-30 Curevac Ag Rna for cancer therapy
CN110267978A (en) 2016-10-07 2019-09-20 得克萨斯大学体系董事会 The T cell of the IL-12 of expression film anchoring for treating cancer

Also Published As

Publication number Publication date
KR20220159479A (en) 2022-12-02
ES2941411T3 (en) 2023-05-22
HRP20230050T1 (en) 2023-03-03
EP3458083A1 (en) 2019-03-27
WO2017201350A1 (en) 2017-11-23
LT3458083T (en) 2023-02-10
KR20190008890A (en) 2019-01-25
IL262501A (en) 2018-12-31
RS63912B1 (en) 2023-02-28
PT3458083T (en) 2023-03-06
RU2018144292A3 (en) 2021-03-10
PL3458083T3 (en) 2023-03-13
US11571463B2 (en) 2023-02-07
US20200376081A1 (en) 2020-12-03
US20210299221A1 (en) 2021-09-30
MX2022008602A (en) 2022-08-11
SI3458083T1 (en) 2023-03-31
EP4186518A1 (en) 2023-05-31
JP2023072056A (en) 2023-05-23
AU2017268397A1 (en) 2019-01-17
AU2017268397B2 (en) 2023-07-06
US11000573B2 (en) 2021-05-11
EP3458083B1 (en) 2022-11-02
US20190125839A1 (en) 2019-05-02
FI3458083T3 (en) 2023-03-01
JP2019516710A (en) 2019-06-20
KR102469450B1 (en) 2022-11-22
RU2769316C2 (en) 2022-03-30
JP7246930B2 (en) 2023-03-28
US10646549B2 (en) 2020-05-12
RU2018144292A (en) 2020-06-18
CN109195621A (en) 2019-01-11
US20240024422A1 (en) 2024-01-25
US20220265774A1 (en) 2022-08-25
CA3024470A1 (en) 2017-11-23
US11311602B2 (en) 2022-04-26
HUE061077T2 (en) 2023-05-28
DK3458083T3 (en) 2023-01-30
MX2018013509A (en) 2019-03-28

Similar Documents

Publication Publication Date Title
SG11201809381XA (en) Polynucleotides encoding interleukin-12 (il12) and uses thereof
SG11201903674YA (en) Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
SG11201909949XA (en) Targeted immunotolerance
SG11201907422RA (en) Anti-tau antibodies and methods of use thereof
SG11201909395TA (en) Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
SG11201909777YA (en) Modulatory polynucleotides
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201805268XA (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201907427YA (en) Engineered transferrin receptor binding polypeptides
SG11201910096RA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201908051RA (en) Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201809594WA (en) Nicotine particles and compositions
SG11201810987TA (en) A thermoplastic optical device